[Bullous autoimmune dermatoses of the mucous membranes].
Bullöse Autoimmundermatosen der Schleimhaut.
Autoantibodies
Blistering skin diseases
Pemphigoid
Pemphigus
Rare skin diseases
Journal
Dermatologie (Heidelberg, Germany)
ISSN: 2731-7013
Titre abrégé: Dermatologie (Heidelb)
Pays: Germany
ID NLM: 9918384885206676
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
accepted:
08
07
2022
pubmed:
26
8
2022
medline:
2
9
2022
entrez:
25
8
2022
Statut:
ppublish
Résumé
Autoimmune bullous diseases (AIBD) comprise a group of organ-specific autoimmune diseases which are characterised by the production of autoantibodies against adhesion molecules and structural proteins of skin and mucosae. Depending on the target protein, AIBD are classified into intraepidermal (pemphigus group) and subepidermal (pemphigoid group, epidermolysis bullosa acquisita, dermatitis herpetiformis) blistering disorders. Depending on the clinical entity, patients can develop blisters, pustules, erosions, and erythema on the skin and mucosae. Bullöse Autoimmundermatosen (BAID) sind eine Gruppe organspezifischer Autoimmunerkrankungen, die durch die Produktion von Autoantikörpern (AAK) gegen Adhäsionsmoleküle bzw. Strukturproteine der Haut und der hautnahen Schleimhäute verursacht werden. Abhängig von den jeweiligen Zielantigenen der AAK werden intraepidermale (Pemphigusgruppe) und subepidermale (Pemphigoidgruppe, Epidermolysis bullosa acquisita, Dermatitis herpetiformis Duhring) BAID unterschieden. Klinisch zeigen sich je nach Krankheitsentität Vesikulae, Bullae, Pusteln, Erosionen und Erytheme an Haut und Schleimhäuten.
Autres résumés
Type: Publisher
(ger)
Bullöse Autoimmundermatosen (BAID) sind eine Gruppe organspezifischer Autoimmunerkrankungen, die durch die Produktion von Autoantikörpern (AAK) gegen Adhäsionsmoleküle bzw. Strukturproteine der Haut und der hautnahen Schleimhäute verursacht werden. Abhängig von den jeweiligen Zielantigenen der AAK werden intraepidermale (Pemphigusgruppe) und subepidermale (Pemphigoidgruppe, Epidermolysis bullosa acquisita, Dermatitis herpetiformis Duhring) BAID unterschieden. Klinisch zeigen sich je nach Krankheitsentität Vesikulae, Bullae, Pusteln, Erosionen und Erytheme an Haut und Schleimhäuten.
Identifiants
pubmed: 36006424
doi: 10.1007/s00105-022-05036-y
pii: 10.1007/s00105-022-05036-y
doi:
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
692-700Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Amber KT, Valdebran M, Grando SA (2018) Paraneoplastic autoimmune multiorgan syndrome (PAMS): beyond the single phenotype of paraneoplastic pemphigus. Autoimmun Rev 17:1002–1010
doi: 10.1016/j.autrev.2018.04.008
Bağcı IS, Horváth ON, Ruzicka T, Sárdy M (2017) Bullous pemphigoid. Autoimmun Rev 16:445–455
doi: 10.1016/j.autrev.2017.03.010
Bédane C, Doffoel Hantz V (2011) Pemphigoïde cicatricielle: revue de la littérature. Ann Dermatol Venereol 138:201–208
doi: 10.1016/j.annder.2011.01.012
van Beek N, Zillikens D, Schmidt E (2021) Bullous autoimmune dermatoses—clinical features, diagnostic evaluation, and treatment options. Dtsch Arztebl Int 118:413–420
pubmed: 34369370
pmcid: 8380840
Cozzani E, Di Zenzo G, Gasparini G, Salemme A, Agnoletti AF, Vassallo C, Caproni M, Antiga E, Marzano AV, Cavalli R, Ocella C, de Simone C, Parodi A (2020) Autoantibody profile of a cohort of 54 Italian patients with linear IgA bullous dermatosis: LAD‑1 denoted as a major auto-antigen of the lamina Lucida subtype. Acta Dermatol Venereol 100:adv70
Deotto ML, Spiller A, Sernicola A, Alaibac M (2022) Bullous pemphigoid: an immune disorder related to aging (review). Exp Ther Med 23:50
doi: 10.3892/etm.2021.10972
Didona D, Di Zenzo G, Joly P (2021a) Paraneoplastic autoimmune multiorgan syndrome. Ital J Dermatol Venereol 156:174–183
doi: 10.23736/S2784-8671.20.06675-4
Didona D, Fania L, Didona B, Eming R, Hertl M, Di Zenzo G (2020) Paraneoplastic dermatoses: a brief general review and an extensive analysis of paraneoplastic pemphigus and paraneoplastic dermatomyositis. Int J Molecular Sci. https://doi.org/10.3390/ijms21062178
doi: 10.3390/ijms21062178
Didona D, Hertl M (2021) Paraneoplastische Autoimmundermatosen. Hautarzt 72:277–287
doi: 10.1007/s00105-021-04773-w
Didona D, Maglie R, Eming R, Hertl M (2019) Pemphigus: current and future therapeutic strategies. Front Immunol 10:1418
doi: 10.3389/fimmu.2019.01418
Didona D, Scarsella L, Fehresti M, Solimani F, Juratli HA, Göbel M, Mühlenbein S, Holiangu L, Pieper J, Korff V, Schmidt T, Sitaru C, Eming R, Hertl M, Pollmann R (2021b) Autoreactive peripheral blood T helper cell responses in bullous pemphigoid and elderly patients with pruritic disorders. Front Immunol 12:569287
doi: 10.3389/fimmu.2021.569287
Genovese G, Venegoni L, Fanoni D, Muratori S, Berti E, Marzano AV (2019) Linear IgA bullous dermatosis in adults and children: a clinical and immunopathological study of 38 patients. Orphanet J Rare Dis 14:115
doi: 10.1186/s13023-019-1089-2
Hofmann SC, Juratli HA, Eming R (2018) Bullous autoimmune dermatoses. J Dtsch Dermatol Ges 16:1339–1358
pubmed: 30395404
Holtsche MM, Zillikens D, Schmidt E (2018) Schleimhautpemphigoid. Hautarzt 69:67–83
doi: 10.1007/s00105-017-4089-y
Juratli HA, Sárdy M (2019) Lineare IgA-Dermatose. Hautarzt 70:254–259
doi: 10.1007/s00105-019-4377-9
Mimouni D, Anhalt GJ, Lazarova Z, Aho S, Kazerounian S, Kouba DJ, Mascaro JM, Nousari HC (2002) Paraneoplastic pemphigus in children and adolescents. Br J Dermatol 147:725–732
doi: 10.1046/j.1365-2133.2002.04992.x
Moro F, Fania L, Sinagra JLM, Salemme A, Di Zenzo G (2020) Bullous pemphigoid: trigger and predisposing factors. Biomolecules 10:1432
doi: 10.3390/biom10101432
Paolino G, Didona D, Magliulo G, Iannella G, Didona B, Mercuri SR, Moliterni E, Donati M, Ciofalo A, Granata G, Ranuzzi P, Falasca V, Calvieri S (2017) Paraneoplastic pemphigus: insight into the autoimmune pathogenesis, clinical features and therapy. IJMS. https://doi.org/10.3390/ijms18122532
doi: 10.3390/ijms18122532
pubmed: 29186863
pmcid: 5751135
Rashid H, Lamberts A, Borradori L et al (2021) European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology—Part I. J Eur Acad Dermatol Venereol 35:1750–1764
doi: 10.1111/jdv.17397
Sánchez-García V, Pérez-Alcaraz L, Belinchón-Romero I, Ramos-Rincón J‑M (2022) Comorbidities in patients with autoimmune bullous disorders: hospital-based registry study. Life. https://doi.org/10.3390/life12040595
doi: 10.3390/life12040595
pubmed: 35455086
pmcid: 9031095
Schmidt E, Rashid H, Marzano AV et al (2021) European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology—Part II. J Eur Acad Dermatol Venereol 35:1926–1948
doi: 10.1111/jdv.17395
Schmidt E, Sticherling M, Sárdy M, Eming R, Goebeler M, Hertl M, Hofmann SC, Hunzelmann N, Kern JS, Kramer H, Nast A, Orzechowski H‑D, Pfeiffer C, Schuster V, Sitaru C, Zidane M, Zillikens D, Worm M (2020) S2k-Leitlinie zur Therapie des Pemphigus vulgaris/foliaceus und des bullösen Pemphigoids: 2019 Update. J Dtsch Dermatol Ges 18:516–527
pubmed: 32413222